Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
iOMEDICO AG clinical trials
The registry lists 53 studies whose lead sponsor is iOMEDICO AG. 14 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 22, 2026.
Keep track of what changes. Save the iOMEDICO AG studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to iOMEDICO AG.
- iOMEDICO AG53 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 50 of 53. Browse all 53 →
- Ivosidenib in Locally Advanced or Metastatic Cholangiocarcinoma With IDH1 R132 Mutation After at Least One Prior Systemic Treatment - an Observational StudyRecruitingNCT06607302
- Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular LymphomaRecruitingNCT05326308
- Fruquintinib in Patients With Metastatic Colorectal CancerRecruitingNCT06787105
- Registry Platform Urologic CancerRecruitingNCT03374267
- Myeloma Registry Platform (MYRIAM)RecruitingNCT03308474
- Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic NeoplasmsRecruitingNCT06043011
- A Non-interventional Study of Melphalan Flufenamide (Melflufen) (Pepaxti®) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (R/RMM)RecruitingNCT07559799
- Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast CancerRecruitingNCT07563595
- Breast Cancer Registry PlatformRecruitingNCT03417115
- Research Platform Myelofibrosis and AnemiaRecruitingNCT06976918
- Registry Platform Ovarian and Endometrial CancerRecruitingNCT05129969
- Registry Platform Gastric/Esophageal Cancer (SAPHIR)RecruitingNCT04290806
- Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic SplenomegalyRecruitingNCT06743035
- Vorasidenib in CNS WHO Grade 2 IDH-mutant Diffuse GliomaRecruitingNCT07240662
- Liver Cancer Registry PlatformActive, not recruitingNCT04510740
- Registry Platform Colorectal CancerActive, not recruitingNCT04867525
- Acalabrutinib in Patients With Chronic Lymphocytic Leukemia With Direct Oral Anticoagulation (CICERO)CompletedNCT05517265
- Ivosidenib (TIBSOVO®) Combined With Azacitidine According to Current SmPCCompletedNCT06181734
- Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT05954780
- Ripretinib (QINLOCK®) According to Current SmPCCompletedNCT06619275
- Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment Regimens.CompletedNCT05253911
- Non-interventional Study of Kyprolis® in Combination With Revlimid® and Dexamethasone or Dexamethasone Alone or in Combination With Darzalex® and Dexamethasone in Multiple Myeloma PatientsCompletedNCT02970747
- Tumour Registry Colorectal CancerCompletedNCT00910819
- Tumour Registry Breast CancerCompletedNCT01351584
- Registry for Molecular Testing, Treatment and Outcome of Patients With Solid Tumors Harboring a NTRK Gene FusionCompletedNCT04557813
- Tumor Registry Pancreatic CancerCompletedNCT02089269
- Non-interventional Study to Evaluate Patient and Healthcare Provider Satisfaction of Daratumumab Use in the Treatment of First-line Daratumumab, Lenalidomide, Dexamethasone (DRd) Multiple Myeloma Patients in Germany Depending on Application Route (sc or iv)CompletedNCT05284591
- Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix® and FOLFIRI or FOLFOX in First Line (VALIDATE)CompletedNCT03043950
- Non-interventional Study of Lenalidomide / Dexamethasone as First Line Therapy in Patients With Multiple MyelomaCompletedNCT02537808
- Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision OncologyCompletedNCT04389541
- Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or FulvestrantCompletedNCT02894398Phase 2
- Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First LineCompletedNCT03462251Phase 3
- Non-interventional Study With Pomalidomide (Imnovid®)CompletedNCT02075996
- Nab-Paclitaxel in Combination With Carboplatin as First-line Therapy in Patients With NSCLCCompletedNCT02799862
- Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Advanced TNBC Under First-line Treatment With Atezolizumab Plus ChemotherapyCompletedNCT03911219
- Prospective Patient Reported Outcomes (PRO) Registry in Patients With Advanced Renal Cell CarcinomaCompletedNCT02537743
- Prospective PRO/QoL Registry for Patients With Bone Metastases of Breast or Prostate CancerCompletedNCT02410044
- Patient Reported Outcomes Registry in Patient With Cancer CachexiaCompletedNCT02983500
- Tumor Registry of Advanced Renal Cell CarcinomaCompletedNCT00610012
- Tumor Registry of Lymphatic NeoplasiaCompletedNCT00889798
- Tumour Registry Lung Cancer (TLK)CompletedNCT01192919
- Patient Preference for Pegfilgrastim (Neulasta®) Application FormsCompletedNCT03619993Not applicable
- A Study to Compare Pertuzumab + Trastuzumab + Vinorelbine vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast CancerWithdrawnNCT03811418Phase 3
- Bone Pain Score Validation InitiativeCompletedNCT02293642
- Non-interventional Study With Nab-Paclitaxel (Abraxane®)CompletedNCT01689610
- Non -Interventional Study-Palliative Therapy of Multiple Myeloma With a Combination of Lenalidomide and DexamethasoneCompletedNCT00911105
- Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)CompletedNCT01266837Phase 4
- Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With BevacizumabCompletedNCT02248571Phase 4
- First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell CarcinomaCompletedNCT01521715Phase 4
- Capecitabine and Bevacizumab ± Vinorelbine in Metastatic Breast CancerCompletedNCT00868634Phase 3